Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817356 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06817356: Recruiting Phase 2 study of Alcohol Use Disorder, sponsored by Eli Lilly and Company.
NCT06817356 is a Phase 2 study of Alcohol Use Disorder that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 300 participants, roughly in line with the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06817356, a Phase 2 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mazdutide
Study Locations (20)
Florida
- Research Centers of America ( Hollywood ) - Hollywood
- K2 Medical Research - Maitland - Maitland
- K2 Medical Research - Maitland
- Clinical Neuroscience Solutions Inc - Orlando
- Clinical Neuroscience Solutions, Inc. - Orlando
- K2 Medical Research - Tampa - Tampa
California
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Synergy San Diego - Lemon Grove
- Headlands Research-Artemis San Diego - San Diego
Arkansas
- Woodland International Research Group - Little Rock
- Woodland Resarch Northwest/ERG - Rogers
Massachusetts
- Adams Clinical - Watertown
- Vitalix Clinical - Worcester
New York
- Richmond Behavioral Associates - Staten Island
- Ichor Research - Syracuse
Arizona
- Headlands Research - Scottsdale - Scottsdale
Georgia
- CenExel iResearch, LLC (CenExel iRA) - Decatur
Louisiana
- DelRicht Research - Mandeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT06817356 shows while recruiting
NCT06817356 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06817356 names 20 study sites across 10 states, led by Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06817356 about?
NCT06817356 is a clinical study titled "A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder". The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
What is the current status of trial NCT06817356?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-02-06. Estimated completion is 2026-08.
What conditions does trial NCT06817356 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT06817356?
The interventions under investigation include: Placebo (DRUG), Mazdutide (DRUG).
Who is sponsoring clinical trial NCT06817356?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817356 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06817356's enrollment target sits among peer trials
300 27th of 184 higher than 156 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI